Stories about research and scientific development at Mount Sinai
Mount Sinai Researchers Receive $13 Million NIH Grant to Study Impact of Genome Sequencing on Children’s Health Outcomes and Health Care Costs
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a grant from the National Institutes of Health for a four-year research program, the NYCKidSeq study, that aims to evaluate how genome sequencing can improve health care management by...
Robotics Symposium in 3D
Ash Tewari, MBBS, MCh, and Ketan Badani, MD, attracted a standing-room-only audience at the American Urological Association (AUA) Annual Meeting in May, when the Mount Sinai physicians led a 3D satellite symposium on complex robotic prostate, kidney, and bladder...
Addiction Institute to Explore Effective Therapies
The Icahn School of Medicine at Mount Sinai recently opened a new Addiction Institute that will address one of the nation’s greatest health concerns by exploring effective treatments for patients with substance abuse problems. “Bringing science to bear on the...
Treating Depression with Software: Technology from Mount Sinai Steps into the Digital Healthcare Universe
A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to...
Exposure to Specific Toxins and Nutrients During Late Pregnancy and Early Life Correlated With Autism Risk
Using evidence found in baby teeth, researchers from The Senator Frank R. Lautenberg Environmental Health Sciences Laboratory and The Seaver Autism Center for Research and Treatment at Mount Sinai found that differences in the uptake of multiple toxic and essential...
Breakthrough Eczema Drug Based on Mount Sinai Research
The U.S. Food and Drug Administration has approved a new biologic drug that is based on seminal research by Emma Guttman-Yassky, MD, Professor of Dermatology, and Medicine (Clinical Immunology), at the Icahn School of Medicine at Mount Sinai. The drug, dupilumab, was...
Mount Sinai Takes Leading Role in Developing New Technique to Treat the Most Devastating Form of Stroke
Spontaneous bleeding in the brain, known as intracerebral hemorrhage (ICH), remains the least treatable and most devastating form of stroke. While it accounts for only 15 percent of all strokes, it is a leading cause of mortality, morbidity, and disability worldwide,...
Study Finds Grandparents and Teachers Often Are Among the First to Suspect Autism
Children who have older siblings or frequent interaction with grandparents are diagnosed with autism spectrum disorders (ASD) earlier than those who do not, according to new research conducted at the Seaver Autism Center for Research and Treatment at Mount Sinai, and...
Pre-existing Immunity to Dengue and West Nile Viruses May Cause Increased Risk in Zika-Infected
As the Zika virus continues to spread rapidly across the globe, it might pose a particular risk to people previously infected with two related viruses, dengue and West Nile, researchers at the Icahn School of Medicine at Mount Sinai have found. Their study, published...